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Abstract
Background: Mutations in the high penetrance breast and ovarian cancer susceptibility gene BRCA1 account for a
significant percentage of hereditary breast and ovarian cancer cases. Genotype-phenotype correlations of BRCA1
mutations located in different parts of the BRCA1 gene have been described previously; however, phenotypic
differences of specific BRCA1 mutations have not yet been fully investigated. In our study, based on the analysis of
a population-based series of unselected breast and ovarian cancer cases in Latvia, we show some aspects of the
genotype-phenotype correlation among the BRCA1 c.4034delA (4153delA) and c.5266dupC (5382insC) founder
mutation carriers.
Methods: We investigated the prevalence of the BRCA1 founder mutations c.4034delA and c.5266dupC in a
population-based series of unselected breast (n = 2546) and ovarian (n = 795) cancer cases. Among the BRCA1
mutation carriers identified in this analysis we compared the overall survival, age at diagnosis and family histories
of breast and ovarian cancers.
Results: We have found that the prevalence of breast and ovarian cancer cases (breast: ovarian cancer ratio) differs
significantly among the carriers of the c.5266dupC and c.4034delA founder mutations (OR = 2.98, 95%CI = 1.58 to
5.62, P < 0.001). We have also found a difference in the prevalence of breast and ovarian cancer cases among the
1
st and 2
nd degree relatives of the c.4034delA and c.5266dupC mutation carriers. In addition, among the breast
cancer cases the c.4034delA mutation has been associated with a later age of onset and worse clinical outcomes
in comparison with the c.5266dupC mutation.
Conclusions: Our data suggest that the carriers of the c.4034delA and c.5266dupC founder mutations have
different risks of breast and ovarian cancer development, different age of onset and prognosis of breast cancer.
Background
Breast cancer is the most prevalent malignancy and the
leading cause of death from cancer among women in
Latvia. Ovarian cancer appears less frequent; however, it
remains a significant cause of cancer mortality in Latvia
and worldwide. Hereditary cancer syndromes account
for up to 5-10% of breast cancer cases and for up to 5-
15% of ovarian cancer cases [1,2]. Germline mutations
of the BRCA1 and BRCA2 genes represent the most
significant and thus far the best characterized genetic
risk factors for breast and ovarian cancer development
[3]. More than 1000 distinct cancer-associated BRCA1
[MIM 113705] mutations have been already described;
however, not all of them are equally pathogenic and
most probably there is a different cancer risk associated
with specific mutations [4]. In sporadic breast carci-
noma, BRCA1 is rarely mutated, although expression
frequently is limited by DNA methylation-induced gene
suppression. The BRCA1 protein has been implicated in
different biological processes, including DNA repair, cell
cycle control, transcriptional regulation, centrosome
duplication and tumour suppressor function [5].
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caused by different BRCA1 mutations are not identical
and can lead to various phenotypes of cancers (geno-
type-phenotype correlations) [6]. Therefore, clinical pre-
sentations, outcome and response to treatment of
tumours can differ significantly depending on the type
of mutations. In the case of pathogenic BRCA1 muta-
tions, it has been previously shown that mutations in
exon 11 (nucleotides 2388-4185) of the BRCA1 gene are
associated with almost equal breast and ovarian cancer
incidence among mutation carriers (breast:ovarian can-
cer ratio) in comparison with mutations in other parts
of the BRCA1 gene. On the other hand, mutations
located 3’ of nucleotide 4185 are usually associated with
a higher risk of breast cancer development and with a
relatively lower ovarian cancer risk [2,6]. Nevertheless,
the genotype-phenotype correlations of the specific
BRCA1 founder mutations c.4034delA (also described as
4153delA (or 4154delA) in exon 11) and c.5266dupC
(5382insC in exon 20) have not been fully investigated.
In this article, we describe some aspects of genotype-
phenotype correlation among the c.4034delA and
c.5266dupC mutation carriers identified in a population-
based screening in Latvia which was observed in the
prevalence of breast and ovarian cancer cases among
the mutation carriers and their 1
st and 2
nd degree rela-
tives, in the age of onset and in the clinical outcomes of
breast cancer.
Methods
The study population is comprised of 2546 unselected
breast cancer patients and 795 unselected ovarian cancer
patients who, during the period from 2000 to 2009,
underwent genetic counselling and BRCA1 founder
mutation analysis at the Hereditary Cancer Outpatient
Clinic of Pauls Stradins Clinical University Hospital in
Riga, Latvia. Screening for the BRCA1 founder mutations
c.4034delA and c.5266dupC was performed in different
patient groups as follows: 1) in all the breast and ovarian
cancer patients irrespective of family history (there were
no exclusion criteria); 2) in patients with other cancer
localizations and in healthy individuals when hereditary
breast and ovarian cancer syndromes were suspected.
The study was approved by the Ethical Committee of
Riga Stradins University. All participants signed informed
consent forms for participation in this study.
The information about the time of establishing breast
cancer diagnosis, the TNM classification and the time
and cause of death of cancer patients was confirmed in
the Latvian Ministry of Health, the “Register of Patients
Suffering from Particular Diseases, Patients with Can-
cer”. The patients for the control group for breast can-
cer survival analysis were randomly selected from the
breast cancer patients who were tested negative for the
BRCA1 founder mutations, matched by tumour size,
nodal status and age at diagnosis. Oestrogen receptor
(ER), progesterone receptor (PR) and HER2/neu expres-
sion status was assessed using a standard immunohisto-
chemical technique. The data on family histories were
obtained from the database of the Hereditary Cancer
Institute (in Riga Stradins University) as reported by
probands. During genetic counselling the following data
were collected using special questionnaires: the number
of cancer cases among the 1
st -4
th degree relatives in
the family with indication of cancer localization in the
affected relatives, the age of onset of cancer disease and
the age of death. The presence of BRCA1 founder muta-
tions c.4034delA and c.5266dupC was determined as
described elsewhere [7].
Statistical analysis was performed using EpiCalc 2000
version 1.02 and SPSS, version 19. We estimated the
survival function with the Kaplan-Meier estimator and
calculated cumulative incidences as one minus survival
function. Differences in survival and cumulative inci-
dence were compared with the Log Rank test. Adjusted
Hazard Ratios (HR) were estimated with Cox propor-
tional hazard regression. Association between cancer
type and mutation was assessed with Odds Ratios (OR)
and associated Mantel-Haenszel 95% Confidence Inter-
vals (CI). Comparison of two independent proportions
was performed by Z-test.
Results
1. Different breast:ovarian cancer ratios among
c.4034delA and c.5266dupC mutation carriers
Molecular analysis of BRCA1 founder mutations among
2546 unselected breast cancer patients has revealed the
presence of mutations in 96 (3.77%) cases, including 25
(0.98%) c.4034delA mutations and 69 (2.70%)
c.5266dupC mutations. From 795 unselected ovarian
cancer patients BRCA1 mutations were identified in 79
(9.90%) cases, including 41 (5.10%) c.4034delA and 38
(4.80%) c.5266dupC mutations.
Among the 107 breast and ovarian cancer patients
who were identified as the mutation c.5266dupC car-
riers, breast cancer cases accounted for 64%; however,
among the 76 breast and ovarian cancer patients
c.4034delA mutation carriers breast cancer cases
accounted only for 32% (OR = 2.98, 95% CI = 1.58 to
5.62, P < 0.001), which reflected the difference in the
breast:ovarian cancer ratios among the carriers of these
founder mutations. The difference in the breast:ovarian
cancer relative risk associated with the c.5266dupC and
c.4034delA founder mutations in this population-based
series was calculated as RR = 1.70 (95% CI = 1.21 to
2.39, P < 0.001).
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Page 2 of 82. Age at diagnosis of breast and ovarian cancer
In this population-based series the median age at diag-
nosis of breast cancer patients among the cases with no
mutations was 60.21 (age range 21-95) years in compari-
son with 51.76 (age range 35-76) years among the
c.4034delA mutation carriers and 46.51 (age range 28-
76) years among the c.5266dupC mutation carriers. The
median age at diagnosis of ovarian cancer cases among
the cases without mutations was 58.57 (age range 30-88)
years in comparison with 53.21 (age range 28-73) years
among the c.4034delA mutation carriers and 49.30 (age
range 35-77) years among the c.5266dupC mutation car-
riers. The linear trends of age-related cumulative inci-
dence of breast cancer cases are shown in Figure 1. We
observed a significant difference in cumulative incidence
of breast cancer among the c.5266dupC and c.4034delA
mutation carriers (c
2 =4 . 3 9 ,w i t h1d e g r e eo ff r e e d o m ,
P = 0.03). The difference in cumulative incidence of
patients without mutations in comparison with the
c.5266dupC (c
2 = 137.57, with 1 degree of freedom, P <
0.001) and c.4034delA (c
2 = 15.27, with 1 degree of
freedom, P = P < 0.001) mutation carriers was also sta-
tistically significant. The difference in age at diagnosis of
ovarian cancer among the c.4034delA and c.5266dupC
mutation carriers and patients without mutations was
not statistically significant (data not shown).
3. Survival analysis of breast cancer patients
The breast cancer survival analysis includes 25 mutation
c.4034delA carriers, 68 mutation c.5266dupC carriers
and 103 patients without mutations, with a median fol-
low-up period of 103 months. There were 36 women
who died from breast cancer (7 in the c.4034delA
group, 11 in the c.5266dupC group and 18 in the
control group) and 13 women who died from causes
other than breast cancer: 5 women died from ovarian
cancer (1 in the c.4034delA group, 3 in the c.5266dupC
group and 1 in the control group), 4 from cancers of
other sites (1 in the c.4034delA group, 1 in the
c.5266dupC group and 2 in the control group) and 4
deaths unrelated to cancer. The last 4 cases were
included in survival analysis, but were counted as the
end of the follow-up period and not as death events.
The mean estimated survival time during a 20 year
follow-up period was calculated as 134 months (95% CI
= 92.58 to 177.00) in the c.4034delA group in compari-
son with 189 months in the c.5266dupC group (95% CI
= 166.75 to 211.43) and 192 months in the control
group (95% CI = 175.54 to 208.83). The cumulative sur-
vival plot is shown in Figure 2. Analysis of the Kaplan-
Meier curves showed that the clinical outcome of breast
cancer patients who were the c.4034delA mutation car-
riers was significantly worse in comparison with the
c.5266dupC mutation carriers (c
2 = 4.32, with 1 degree
of freedom, P = 0.038) and with patients from the con-
trol group (c
2 = 7.05, with 1 degree of freedom, P =
0.008). We did not observe any significant difference in
tumour staging and lymph node status in both groups
of mutation carriers (Table 1).
We also performed Cox regression analysis among
breast cancer patients where cancer related mortality
was used as the end point. The presence of the
c.4034delA founder mutation remained an independent
predictor of unfavourable prognosis in multivariable
analysis among BRCA1 mutation carriers (Table 2). The
presence of any BRCA1 founder mutation was not
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Figure 1 Age-related cumulative incidence of breast cancer
cases among c.4034delA and c.5266dupC mutation carriers
and patients without mutations.
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Figure 2 Overall survival of breast cancer patients - c.4034delA
and c.5266dupC mutation carriers and patients without
mutations.
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Page 3 of 8significantly associated with unfavourable prognosis in
multivariable analysis among all hereditary and sporadic
breast cancer patients (Table 3). Hormone receptor sta-
tus was not included in multivariate analysis, because it
was available only for 52% of the patients. However, in
univariable analysis hormone receptor negativity was
significantly associated with unfavourable prognosis only
among the patients without BRCA1 mutations (HR =
0.18, 95% CI = 0.03 to 0.98, P = 0.04), whereas the
impact of hormone receptor status on the prognosis of
breast cancer among BRCA1 mutation carriers was not
statistically significant (HR = 1.09, 95% CI = 0.21 to
5.67, P = 0.91).
4. Different prevalence of breast and ovarian cancer cases
among relatives of c.4034delA and c.5266dupC mutation
carriers
Hereditary cancer institute database contains informa-
tion about 207 families of BRCA1 founder mutation car-
riers (including 79 families of c.4034delA and 128
families of c.5266dupC mutation carriers) who were
identified during genetic screening in Latvia. Overall,
the c.4034delA mutation carriers reported about cancer
cases in their families more frequently in comparison
with the c.5266dupC mutation carriers (the average
amount of individuals ill with cancer in c.4034delA
families was 2.9 individuals per family in comparison
with 2.1 individuals per family reported in the
c.5266dupC group, P = 0.009). The amount of “breast
cancer families” with a history of only breast cancer
cases and without ovarian cancer cases (at least two 1
st
or 2
nd (related through a man) degree relatives) was
higher among the c.5266dupC mutation carriers,
whereas the amount of “breast and ovarian cancer
families” with a history of ovarian cancer cases with or
without breast cancer cases was higher among the car-
riers of the c.4034delA mutation. Probands, c.4034delA
mutation carriers, have reported more frequently about
multiple cases of any cancer (3 or 4) among the 1
st and
2
nd degree relatives in their families in comparison with
the c.5266dupC mutation carriers (Table 4).
Due to the polygenic inheritance of breast and ovarian
cancers, clustering of specific cancer localizations within
Table 1 Clinical characteristics of patients included in the survival analysis
Variable c.4034delA c.5266dupC Control
N. of patients 25 68 103
Median age of onset (years) 51.7 46.5 54.9
T4 - n. (%) 5 (20%) 10 (15%) 7 (7%)
T3 - n. (%) 1 (4%) 3 (4%) 13 (13%)
T2 - n. (%) 14 (56%) 43 (63%) 63 (61%)
T1 - n. (%) 5 (20%) 12 (18%) 20 (19%)
Axillary node positive - n. (%) 14 (56%) 32 (47%) 44 (43%)
ER/PR positive (%) 50% 15% 70%
HER2 positive (%) 22% 11% 10%
ER/PR/HER2 (Triple) negative (%) 50% 79% 24%
N. of patients dead from cancer during follow-up period 9 (36%) 15 (22%) 21 (20%)
Table 2 Multivariable Cox-regression analysis of BRCA1
c.4034delA and c.5266dupC mutation carriers breast
cancer patients
Variable n HR 95%CI P-value
BRCA1 mutations:
c.4034delA 25 2.76 1.13 - 6.70 0.02
c.5266dupC 68
Tumor size:
< 5 cm 74 0.36 0.15 - 0.86 0.02
> 5 cm 19
Axillary node:
Negative 44 0.34 0.13 - 0.89 0.03
Positive 49
Age at diagnosis:
< 50 51 1.53 0.65 - 3.61 0.32
>5 0 4 2
Table 3 Multivariable Cox-regression analysis of breast
cancer patients
Variable n HR 95%CI P-value
BRCA1 mutations:
Mutation present 93 1.10 0.81 - 1.48 0.54
Mutation absent 103
Tumor size:
< 5 cm 157 0.68 0.49 - 0.94 0.02
> 5 cm 39
Axillary node:
Negative 103 0.34 0.37 - 0.77 < 0.01
Positive 93
Age at diagnosis:
< 50 89 1.19 0.66 - 2.17 0.55
> 50 107
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unspecific bias of results obtained by analysing family
histories. To overcome this problem we also investigated
the prevalence of breast, ovarian and other cancer locali-
zations among all the 1
st and 2
nd degree relatives of the
carriers of both BRCA1 founder mutations irrespective
of family composition. The prevalence of different can-
cer localizations among all the 1
st and 2
nd degree rela-
tives of the c.4034delA and c.5266dupC mutation
carriers is shown in Table 5.
Discussion
In this study we investigated the prevalence of the most
common BRCA1 founder mutations in a population-
based series of breast and ovarian cancer cases in Latvia.
Over the past several years, genetic counselling and
screening of BRCA1 founder mutations have covered
more than 50% of all breast and ovarian cancer cases
registered in Latvia each year, thus providing informa-
tion about the prevalence of hereditary cancer syn-
dromes and BRCA1 founder mutations in unselected
groups of breast and ovarian cancer patients. The fact
t h a tw ei n v e s t i g a t e dt h ep r e v a l e n c eo fo n l y2s p e c i f i c
founder mutations is the major limitation of our study;
however, according to the already published data, these
2 founder mutations account for more than 80% of all
the BRCA1 mutations that were found among the can-
cer patients in Latvia [8,9]. Several population-based stu-
dies performed in neighbour countries of Latvia
(Lithuania, Belarus and Poland) have demonstrated that
3 founder mutations - c.4034delA, c.5266dupC and
c.181T > G (300T/G) - are the most widespread BRCA1
founder mutations in the southern Baltic region [10-14].
Previous studies in Latvia have shown that the c.181T/G
mutation accounts for only 6-10% of the identified
BRCA1 mutations when genetic analysis had been per-
formed in selected early-onset breast and ovarian can-
cers patients [8] or in specific Latvian regions [9].
Nevertheless, according to our estimation the prevalence
of the c.181T/G founder mutation among unselected
breast and ovarian cancer patients in Latvia is much
lower. The exact prevalence of BRCA1 founder muta-
tions in Latvia is difficult to investigate due to relatively
high heterogeneity of the Latvian population; however,
in the analysis of a population screening of hereditary
cancer syndromes in the Valka district of Latvia, the
prevalence of BRCA1 founder mutations in the Latvian
population was estimated at approximately 0.05% [7].
In our study we also found some phenotypic varia-
tions of hereditary breast and ovarian cancer syndromes
Table 4 Family histories of BRCA1 c.4034delA and c.5266dupC mutations carriers
Types of family histories c.4034delA c.5266dupC 95% CI P-value
No data about cancer cases among 1
st and 2
nd degree relatives 9% (7) 22%(28) 2.44-23.56 0.02
At least 3 cancer cases among 1
st and 2
nd degree relatives (including breast and ovarian) 48% (38) 29% (37) 4.46-33.54 0.008
At least 3 cancer cases among 1
st and 2
nd degree relatives (without breast and ovarian) 14% (11) 6% (8) -2.05-17.45 0.08
At least 4 cancer cases among 1
st and 2
nd degree relatives (including breast and ovarian) 30% (24) 15% (19) 2.14-27.86 0.01
Breast cancer families
1 9% (7) 24% (31) 4.25-25.75 0.01
Breast and ovarian cancer families
2 34% (27) 18% (23) 2.61-29.39 0.01
Total amount of families included 79 128
1 - Breast cancer families - all families with at least two 1
st or 2
nd (related through a man) degree relatives having breast cancer but without ovarian cancer cases
in family.
2 - Breast and ovarian cancer families - all families with at least two 1
st or 2
nd (related through a man) degree relatives having breast or ovarian cancers.
Table 5 Prevalence of different cancer localizations among 1
st and 2
nd degree relatives of probands who were BRCA1
c.4034delA and c.5266dupC mutation carriers (in % of all the reported cancer cases in each group)
Cancer site c.4034delA c.5266dupC 95% CI P-value
Breast 19.0% 34.0% 7.16 to 22.84 0.0002
Ovary 19.0% 8.0% 4.66 to 17.34 0. 0003
Other gynaecological cancers* 16.0% 8.0% 1.94 to 14.06 0.006
Colon and rectum 2.6% 3.1% -2.75 to 3.75 n.s
Pancreas 1.3% 1.3% -2.35 to 2.35 n.s
Prostate 1.7% 2.4% -2.12 to 3.52 n.s
Stomach 11.3% 9.6% -4.00 to 7.40 n.s
Lung 6.5% 2.7% -0.28 to 7.88 0.059
Total amount of relatives reported as having cancer 230 290
* - Other gynaecological cancers include ovarian, uterine and cervical cancer cases when exact localization of cancer was unknown.
n.s. - non-significant
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riers. First of all, we observed a significant difference in
the prevalence of c.4034delA and c.5266dupC mutation
carriers among the breast and ovarian cancer patients.
The breast:ovarian cancer ratio was higher among the
c.5266dupC mutation carriers and lower among the
c.4034delA mutation carriers. Despite the fact that some
previous reports have shown an almost equal breast:
ovarian cancer ratio among the c.4034delA and
c.5266dupC mutation carriers in Latvia, in these studies
genetic analysis was performed in relatively small hospi-
tal-based cohorts that can explain these discrepancies
[8,9]. BRCA1 c.4034delA was initially described as a low
penetrance breast cancer mutation [15]. Several other
reports have demonstrated an increased prevalence of
ovarian cancer cases among the c.4034delA mutation
carriers [12-14]. In the analysis of hospital-based series
of breast and ovarian cancer cases in Belarus the breast:
ovarian cancer ratio among the c.4034delA and
c.5266dupC mutation carriers was similar to the breast:
ovarian cancer ratio obtained in our population-based
series [13].
Several studies have shown some other phenotypic
variations besides breast:ovarian cancer ratios associated
with mutations, located in different parts of the BRCA1
gene. Satagopan et al found that the estimated lifetime
risk of ovarian cancer development were two times as
high for the c.68_69delAG (185delAG) mutation (66%)
than for the c.5266dupC mutation (29%) [16]. Al-Mulla
et al showed that age-related expressivity and pene-
trance of breast and ovarian cancers depended on the
mutation position in the BRCA1 gene and differed
among the carriers of various mutations located in
exons 2, 11 and 13 [17].
The genotype-phenotype correlation effect among the
c.4034delA and c.5266dupC mutation carriers observed
in our study had two other interesting features. The
median age of onset of breast and ovarian cancers
among the c.5266dupC mutation carriers was smaller
than among the c.4034delA mutation carriers. A similar
trend in the age of onset of breast cancer cases among
the c.4034delA and c.5266dupC mutation carriers was
previously shown in a hospital-based series of Belarusian
breast cancer patients; however, in this report the med-
ian age at diagnosis of breast cancer was lower than in
our population-based series (48 years in patients without
mutations, 43 years in c.5266dupC carriers and 44 years
in c.4034delA carriers) [13].
Despite many conflicting reports about the prognostic
significance of BRCA1 mutations in breast cancer
patients (where patients with different mutations were
usually combined in common groups) [18-20], the influ-
ence of individual BRCA1 mutations on the clinical out-
comes of breast cancer patients has not been fully
investigated. In our study we observed a worse clinical
outcome for the c.4034delA mutation carriers in com-
parison with the c.5266dupC mutation carriers and the
sporadic breast cancer patients. To some extent, this
observation can be attributed to the way a part of the
patients were referred to genetic counselling. In many
cases, patients were counselled when they were admitted
to hospital due to a recurrence of the cancer process or
appearance of cancers in other sites. Among the
c.5266dupC mutation carriers, more than 20% of breast
cancer patients were diagnosed with contralateral breast
cancer, when the primary site had been successfully
treated in some cases more than 20 years ago. Among
the carriers of the c.4034delA mutation such cases were
observed less frequently (there was only one case with a
disease-free period of 10 years until contralateral breast
cancer was diagnosed); however, there was a substantial
amount of patients with a progression of primary breast
cancer processes which dramatically reduced survival in
many cases. In spite of this fact, worse overall survival
among the c.4034delA mutation carriers was not asso-
ciated with an advanced stage at diagnosis. The amount
of cases with locally advanced and node positives breast
cancers did not differ significantly among all groups of
patients included in the survival analysis. Furthermore,
the multivariable analysis has shown that the presence
of the c.4034delA mutation remained an independent
predictive factor. On the other hand, improved survival
among the c.5266dupC mutation carriers could not be
attributed to prophylactic surgery or increased surveil-
lance strategies. Indeed, these options have become
available for the breast cancer patients with BRCA1
mutations in Latvia just recently which might explain a
relatively high amount of contralateral breast cancer
cases among the carriers of both BRCA1 founder
mutations.
Taken together, all the described above features show
several aspects of genotype-phenotype correlation
among the carriers of 2 specific BRCA1 founder muta-
tions. Based on these data we can suggest that the car-
riers of the c.4034delA and c.5266dupC founder
mutations have different risks of breast and ovarian can-
cer development, different age of onset and prognosis of
breast cancer. The evaluation of the exact risk of specific
genetic alterations in breast and ovarian susceptibility
genes and possible synergistic effects between them can
lead to a more precise prediction of the individual risk
of developing specific cancers in hereditary breast and
ovarian cancer patients. According to the suggestions of
Mavaddat et al further decision about cancer surveil-
lance and risk reducing strategies should take into
account the individual risk differences based on the eva-
luation of the status of different genetic susceptibility
factors [3]. For example, due to the genotype-phenotype
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have a more significant predisposition to ovarian cancer
than the c.5266dupC mutation carriers. This can suggest
a much stronger indication of risk-reducing salpingo-
oophorectomy among the carriers of this founder muta-
tion. Although the c.5266dupC founder mutation in this
study was associated with better prognosis, the risk of
breast cancer among asymptomatic mutation carriers as
well as the risk of contralateral breast cancer among
breast cancer patients, carriers of this founder mutation,
remains high. This indicates the necessity of intensive
surveillance strategies with a recommendation of risk-
reducing bilateral mastectomy for the carriers of this
mutation. Several studies have shown that risk-reducing
bilateral mastectomy reduces the risk of breast cancer
among BRCA1 mutation carriers by approximately 90%
and additional risk-reducing bilateral salpingo-oophor-
ectomy improves this parameter by only 5% to a total of
95% [21,22]. These data suggest that for carriers of the
c.5266dupC mutation risk-reducing bilateral mastectomy
without salpingo-oophorectomy can be sufficient risk-
reducing option, especially for women of childbearing
age.
Despite their approved effectiveness, most cancer pre-
ventive strategies frequently reduce the quality of life of
patients and are usually associated with a unique set of
social, emotional and sexual factors for BRCA1 mutation
carriers and their family members which can influence
the decision making processes in many cases [23,24].
This issue indicates the importance of further clinical
studies to evaluate the significance of different cancer
prevention options among the carriers of specific genetic
alterations in BRCA1 and other breast and ovarian can-
cer susceptibility genes.
Conclusions
In a population-based series of unselected breast and
ovarian cancer cases in Latvia, the prevalence of breast
cancer cases among the c.5266dupC mutation carriers
was significantly higher in comparison with the
c.4034delA mutation carriers, whereas the prevalence of
ovarian cancer cases was almost similar. Among the
c.4034delA mutation carriers, breast cancers were diag-
nosed at a later age and had worse clinical outcomes in
comparison with the c.5266dupC mutation carriers.
Based on our data we can suggest that carriers of the
c.4034delA and c.5266dupC founder mutations have dif-
ferent risks of breast and ovarian cancer development,
different age of onset and prognosis of breast cancer.
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